Better biofactories

STAFFORDSHIRE, U.K.—Cobra Biomanufacturing developed a method that provides cleaner biologics
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STAFFORDSHIRE, U.K.—Increasingly, scientists are using bacteria to produce a variety of products as therapeutics as well as for other applications. Unfortunately, endogenous proteins and metabolic products within the microbes can contaminate and seriously compromise the desired product. With an eye to eliminating the genes that produce these contaminants, scientists at Cobra Biomanufacturing developed a method that offers higher efficiencies than random recombination and does not rely on exogenous recombinases or transposases. They presented their work in Applied and Environmental Microbiology (2006, 72, 2520-2525).
 
The researchers relied on Xer recombinases, enzymes that naturally occur in most bacterial strains, to remove ("Xer"-cise) target genes in E. coli and B. subtilis strains, and used PCR to confirm their results. With E. coli, they deleted a gene responsible for adding an immunogenic myristoyl group to lipid A and thereby reduced the endotoxicity of the microbe for plasmid DNA production. Similarly, in B. subtilis, they were able to delete the genes responsible for proteases that degrade secreted recombinant proteins.
 
The researchers expect that their technique will become more widely applicable as scientists discover more microbes that carry Xer-sensitive recombination sequences and foresee the possible application of this technology in selective gene removal in eukaryotic organisms.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue